Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma

Journal of Surgical Oncology

Volumn 106, Issue 3, 2012, Pages 304-310

  Li, Yin ^a   Chen, Chuang Qi ^a   He, Yu Long ^a   Cai, Shi Rong ^a   Yang, Dong Jie ^a   He, Wei Ling ^a   Xu, Jian Bo ^a   Zan, Wen Hua ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

c Met; E cadherin; gastric carcinoma (GC); hepatocyte growth factor (HGF); prognosis

Indexed keywords

SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UVOMORULIN;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CYTOPLASM; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STOMACH CARCINOMA; TISSUE MICROARRAY; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CARCINOMA; CYTOPLASM; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; STOMACH NEOPLASMS;

EID: 84864392890     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23008     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, et al.: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Pisani P, Bray F, Parkin DM,: Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002; 97: 72-81.
3. Vogelstein B, Kinzler KW,: Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799.
4. Yoo CB, Jones PA,: Epigenetic therapy of cancer: Past, present and future. Nat Rev Drug Discov 2006; 5: 37-50.
5. Zheng L, Wang L, Ajani J, et al.: Molecular basis of gastric cancer development and progression. Gastric Cancer 2004; 7: 61-77.
6. Boros P, Miller CM,: Hepatocyte growth factor: A multifunctional cytokine. Lancet 1995; 345: 293-295.
7. Liu ZX, Yu CF, Nickel C, et al.: Hepatocyte growth factor induces ERK-dependent paxillin phosphorylation and regulates paxillin-focal adhesion kinase association. J Biol Chem 2002; 277: 10452-10458.
8. Zhou HY, Wong AS,: Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology 2006; 147: 2557-2566.
9. Han SU, Lee JH, Kim WH, et al.: Significant correlation between serum level of hepatocyte growth factor and progression of gastric carcinoma. World J Surg 1999; 23: 1176-1180.
10. Lee J, Seo JW, Jun HJ, et al.: Impact of MET amplification on gastric cancer: Possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 2011; 25: 1517-1524.
11. Drebber U, Baldus SE, Nolden B, et al.: The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep 2008; 19: 1477-1483.
12. Gumbinera BM,: Regulation of cadherin adhesive activity. J Cell Biol 2000; 148: 399-404.
13. Yagi T, Takeichi M,: Cadherin superfamily genes: Functions, genomic organization, and neurologic diversity. Genes Dev 2000; 14: 1169-1180.
14. Palacios F, Price L, Schweitzer J, et al.: An essential role for ARF6-regulated membrane traffic in adherens junction turnover and epithelial cell migration. EMBO J 2001; 20: 4973-4986.
15. Tannapfel A, Wittekind C, Yasui W, et al.: Effect of hepatocyte growth factor on the expression of E- and P-cadherin in gastric carcinoma cell lines. Virchows Archiv 1994; 425: 139-144.
16. Han SU, Lee HY, Lee JH, et al.: Modulation of E-cadherin by hepatocyte growth factor induces aggressiveness of gastric carcinoma. Ann Surg 2005; 242: 676-683.
17. Miura H, Nishimura K, Tsujimura A, et al.: Effects of hepatocyte growth factor on E-cadherin-mediated cell-cell adhesion in DU145 prostate cancer cells. Urology 2001; 58: 1064-1069.
18. Anderson MR, Harrison R, Atherfold PA, et al.: Met receptor signaling: A key effector in esophageal adenocarcinoma. Clin Cancer Res 2006; 12: 5936-5943.
19. Mullaney PJ, Wadley MS, Hyde C, et al.: Appraisal of compliance with the UICC/AJCC staging system in the staging of gastric cancer. Union Internacional Contra la Cancrum/American Joint Committee on Cancer. Br J Surg 2002; 89: 1405-1408.
20. Kallioniemi OP, Wagner U, Kononen J, et al.: Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001; 10: 657-662.
21. Xie LQ, Bian LJ, Li Z, et al.: Altered expression of E-cadherin by hepatocyte growth factor and effect on the prognosis of nasopharyngeal carcinoma. Ann Surg Oncol 2010; 17: 1927-1936.
22. Geiger TR, Peeper DS,: Metastasis mechanisms. Biochim Biophys Acta 2009; 1796: 293-308.
23. Hinck L, Nathke IS, Papkoff J, et al.: Dynamics of cadherin/catenin complex formation: Novel protein interactions and pathways of complex assembly. J Cell Biol 1994; 125: 1327-1340.
24. Wu H, Lotan R, Menter D, et al.: Expression of E-cadherin is associated with squamous differentiation in squamous cell carcinomas. Anticancer Res 2000; 20: 1385-1390.
25. Chang HW, Chow V, Lam KY, et al.: Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Cancer 2002; 94: 386-392.
26. Kim CH, Kim JH, Kahng H, et al.: Change of E-cadherin by hepatocyte growth factor and effect on prognosis of hypopharyngeal carcinoma. Ann Surg Oncol 2007; 14: 1565-1574.
27. Li G, Schaider H, Satyamoorthy K, et al.: Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 2001; 20: 8125-8135.
28. Nakamura Y, Matsubara D, Goto A, et al.: Constitutive activation of c-Met is correlated with c-Met overexpression and dependent on cell-matrix adhesion in lung adenocarcinoma cell lines. Cancer Sci 2008; 99: 14-22.
29. Maroni P, Bendinelli P, Matteucci E, et al.: HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-kappaB. Carcinogenesis 2007; 28: 267-279.
30. Zhou HY, Wan KF, Ip CK, et al.: Hepatocyte growth factor enhances proteolysis and invasiveness of human nasopharyngeal cancer cells through activation of PI3K and JNK. FEBS Lett 2008; 582: 3415-3422.
31. Spix JK, Chay EY, Block ER, et al.: Hepatocyte growth factor induces epithelial cell motility through transactivation of the epidermal growth factor receptor. Exp Cell Res 2007; 313: 3319-3325.
32. Ye M, Hu D, Tu L, et al.: Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells. Invest Ophthalmol Vis Sci 2008; 49: 497-504.
33. Reshetnikova G, Troyanovsky S, Rimm DL,: Definition of a direct extracellular interaction between Met and E-cadherin. Cell Bio Int 2007; 31: 366-373.
34. Thompson EW, Newgreen DF, Tarin D,: Carcinoma invasion and metastasis: A role for epithelial-mesenchymal transition? Cancer Res 2005; 65: 5991-5995.
35. Grotegut S, von Schweinitz D, Christofori G, et al.: Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J 2006; 25: 3534-3545.
36. Horiguchi K, Shirakihara T, Nakano A, et al.: Role of Ras signaling in the induction of snail by transforming growth factor-beta. J Biol Chem 2009; 284: 245-253.
37. Shirakihara T, Saitoh M, Miyazono K,: Differential regulation of epithelial and mesenchymal markers by deltaEF1 proteins in epithelial mesenchymal transition induced by TGF-beta. Mol Biol Cell 2007; 18: 3533-3544.
38. Hiscox S, Jiang WG,: Hepatocyte growth factor/scatter factor disrupts epithelial tumour cell-cell adhesion: Involvement of beta-catenin. Anticancer Res 1999; 19: 509-517.
39. Kim BS, Cho SW, Min SK, et al.: Differences in prognostic factors between early and advanced gastric cancer. Hepatogastroenterology 2011; 58: 1032-1040.
40. Saito H, Osaki T, Murakami D, et al.: Macroscopic tumor size as a simple prognostic indicator in patients with gastric cancer. Am J Surg 2006; 192: 296-300.
41. Bilici A, Uygun K, Seker M, et al.: The effect of tumor size on overall survival in patients with pT3 gastric cancer: Experiences from 3 centers. Onkologie 2010; 33: 676-682.